Delphia (Usa) Inc. Biogen Inc. Transaction History

Delphia (Usa) Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $120,123 - $165,639	-617 Reduced 32.7%	1,270 $339,000
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $63,576 - $75,603	-339 Reduced 15.23%	1,887 $385,000
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $58,906 - $74,218	304 Added 15.82%	2,226 $469,000
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $430,374 - $553,093	1,922 New	1,922 $461,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Delphia (Usa) Inc., based on Form 13F filings with the SEC.

Stay updated on Delphia (Usa) Inc. with notifications on news.